MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Cognitive dysfunction"

  • 2017 International Congress

    Effects of zonisamide, an anti-parkinsonian drug, on cognition and BPSD in DLB patients: A post-hoc analysis of DLB Ph2 study

    M. Murata, T. Odawara, O. Konishi, M. Nakamura, K. Kosaka (Tokyo, Japan)

    Objective: Based on the results of a phase 2 study to evaluate the efficacy of zonisamide in improving parkinsonism accompanying dementia with Lewy Bodies (DLB),…
  • 2017 International Congress

    Decisional capacity for Goals of Care in Parkinson’s Disease with Cognitive Concerns

    M. Abu Snineh, R. Camicioli, J. Miyasaki (Jerusalen, Israel)

    Objective: We sought to assess decisional capacity (DC) for Goals of Care (GOC) using the MacArthur Competence Assessment Tool (MacCAT) for Parkinson’s disease (PD) patients…
  • 2017 International Congress

    Action Verb Generation as a marker of cognitive function in Parkinson disease

    O. Yerokhin, K. Smith (Worcester, MA, USA)

    Objective: We investigated action-verb generation in relation to cognitive function and motor severity in patients with Parkinson disease (PD). Background: PD causes speech and language…
  • 2017 International Congress

    Fluency boost from walking in Parkinson’s disease

    O. Barthelemy, R. Salazar, S. Neargarder, J. DeGutis, T. Ellis, A. Cronin-Golomb (Boston, MA, USA)

    Objective: Examine the impact of a motor task on verbal fluency in individuals with Parkinson’s disease (PD) Background: Dual-tasking, in which individuals engage simultaneously in…
  • 2017 International Congress

    Parkinson’s disease GWAS risk loci and symptom progression

    K. Paul, J. Schulz, J. Bronstein, C. Lill, B. Ritz (los angeles, CA, USA)

    Objective: To assess whether GWAS identified Parkinson’s disease (PD) risk loci also influence symptom progression among patients.  Background: Genetic factors have a considerable influence on…
  • 2017 International Congress

    Diffusion tensor imaging changes in the corpus callosum and cognitive impairment in Parkinson’s disease

    I. Bledsoe, D. Merkitch, G. Stebbins, B. Bernard, J. Goldman (San Francisco, CA, USA)

    Objective: To evaluate diffusion characteristics of the corpus callosum in Parkinson’s disease (PD) patients with varying degrees of cognitive impairment using Diffusion Tensor Imaging (DTI).…
  • 2017 International Congress

    Investigating the Association between Anxiety and Cognitive Impairment in Parkinson’s Disease: A Descriptive Study

    A. Toft, J. Yang, G. Byrne, J. O'Sullivan, L. Mitchell, D. Copland, N. Dissanayaka (Brisbane, Australia)

    Objective: This study investigated the relationship between anxiety and cognitive impairment in PD. Background: Anxiety and cognitive impairment are prevalent non-motor complications in PD. The…
  • 2017 International Congress

    Screening of cognitive impairment in Huntington’s disease with the Parkinson’s Disease – Cognitive Rating Scale (PD-CRS)

    S. Martinez-Horta, A. Horta-Barba, J. Perez-Perez, J. Pagonabarraga, J. Marin-Lahoz, J. Kulisevsky (Barcelona, Spain)

    Objective: To explore the psychometric properties of the PD-CRS as compared to two commonly used measures (the MMSE and the UHDRS Cognitive score) for detecting…
  • 2017 International Congress

    Neuropsychological profile of corticobasal degeneration, progressive supranuclear palsy and frontotemporal dementia patients

    M.M. Carmona-Abellan, M. Riverol, M. Recio, B. Echeveste, L. Imaz, R. Luquin (Pamplona, Spain)

    Objective: To study and compare the neuropsychological profile of patients with corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), non-fluent progressive aphasia (NFPA) and frontotemporal behavioral…
  • 2017 International Congress

    Development and validation of an alternative version of the Parkinson’s Disease-Cognitive Rating Scale

    R. Fernandez-Bobadilla, S. Martinez-Horta, J. Marin-Lahoz, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

    Objective: To develop and validate an alternative form of the PD-CRS (PD-CRS/AF) with the objective of providing a reliable and fully equivalent method of reassessment…
  • « Previous Page
  • 1
  • …
  • 98
  • 99
  • 100
  • 101
  • 102
  • …
  • 128
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley